---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-350445"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-08-14T12:00:16+00:00"
generated_at: "2026-08-14T12:06:26.698402+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 net loss $18.1M; completes PYNNACLE enrollment, NDA planned Q1 2027

## Summary
- Net loss $18.1M for Q2 2026 vs $21.2M in Q2 2025; R&D expenses down to $14.7M from $18.4M.
- Enrollment completed for primary analysis in Phase 2 monotherapy portion of PYNNACLE trial for platinum-resistant/refractory ovarian cancer.
- NDA submission for rezatapopt accelerated approval planned Q1 2027.
- Cash $79.4M as of June 30, 2026, down from $112.9M at Dec 31, 2025; runway through Q2 2027.

## SEC filing metadata
- accession: 0001193125-26-350445
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-08-14T12:00:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/0001193125-26-350445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-350445
- JSON: https://secwatch.observer/filing/0001193125-26-350445.json
- Plain text: https://secwatch.observer/filing/0001193125-26-350445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.